Search Results (5,449)

Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by inflammation, oxidative stress, tear film instability, and secretory dysfunction. This study investigated the protective effects of Lute-gen^®, a lutein and zeaxanthin-based formulation, in both in vitro and in vivo DED models. Human corneal epithelial (HCE-T) cells were stimulated with TNF-α, while dry eye was induced in female Sprague–Dawley rats using subcutaneous scopolamine (SCP) administration. In HCE-T cells, Lute-gen^® showed no cytotoxicity, restored cell viability, reduced intracellular ROS, and was associated with increased expression of antioxidant-related markers (Nrf2, HO-1, SOD, CAT, and GPx), reduced expression of inflammatory mediators (TLR4/MyD88/NF-κB/NLRP3), and increased expression of AQP3 and AQP5. In SCP-induced rats, Lute-gen^® significantly improved tear secretion and reduced corneal fluorescein staining. Histopathological analyses revealed restoration of conjunctival goblet cells, mucin staining, corneal epithelial integrity, acinar area and cell density, and lacrimal gland architecture, with reduced inflammatory infiltration. Immunofluorescence further demonstrated reduced TLR4 and MMP9 immunoreactivity and decreased CD68⁺ inflammatory cell infiltration. Molecular analyses showed reduced expression of inflammatory cytokines and NF-κB/MAPK/MMP signaling-related inflammatory mediators, together with restoration of AQP1, AQP3, and AQP5 expression in corneal tissues. Collectively, these findings suggest that Lute-gen^® treatment was associated with improvements in dry eye-related pathological changes, including restoration of antioxidant-related markers, attenuation of inflammatory responses, restoration of aquaporin expression, and preservation of ocular surface and lacrimal gland integrity. These preclinical findings support further mechanistic investigations and the future clinical evaluation of Lute-gen^® as a potential nutritional intervention for dry eye disease. Full article

Background: Chemoresistance remains a major obstacle in managing cholangiocarcinoma (CCA). The cannabis plant contains several phytocannabinoids, including cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN), which exhibit anticancer properties. However, to the best of our knowledge, their effects on CCA have not been previously investigated. This study aimed to explore the molecular mechanisms underlying the anticancer effects of CBD, CBG, and CBN in CCA cells. Methods: KKU-100 and KKU-452 cells were treated with varying concentrations of CBD, CBG, and CBN for 24 and 48 h. Cytotoxicity was assessed using the MTT assay, and half maximal inhibitory concentration (IC₅₀) values were calculated. KKU 452 cells were further analyzed for apoptosis, mitochondrial membrane potential (MMP), and Ki67 expression using flow cytometry. Proteomics profiling was performed to compare the effect of these cannabinoids with those of gefitinib and cisplatin. Results: Monotherapy with CBD, CBG, or CBN induced dose-dependent cytotoxicity at 24 and 48 h with lower IC₅₀ values than those of cisplatin and comparable efficacy to that of gefitinib. At low doses, CBD, CBG, and CBN induced early apoptosis, while higher doses triggered late apoptosis. MMP loss increased by 2.5-, 4.9-, and 1.7-fold, respectively, after 6 h. Ki67, highly expressed in KKU-452 cells (Ki67-positive ratio = 3.16 ± 0.16), was significantly reduced after the cannabinoid treatment, with Ki67-positive ratios of 0.38 ± 0.22, 0.38 ± 0.13, and 0.32 ± 0.23 for CBD, CBG, and CBN, respectively. Proteomics analysis identified 2781 proteins affected by CBD, CBG, CBN, cisplatin, and gefitinib. All three cannabinoids downregulated key upstream regulatory proteins (LARP1, TFEB, and BCR). Similar patterns of LARP1 and TFEB downregulation were also observed with cisplatin and gefitinib. CBN showed the closest similarity to cisplatin, followed by gefitinib, by targeting CDK4/6 and PCGEM1 proteins. CBD and CBG exhibited the greatest similarity to each other, also influencing MASTL expression. Conclusions: CBD, CBG, and CBN exhibit potential anticancer activity in CCA by suppressing proliferation, reducing Ki67 expression, and inducing apoptosis through MMP disruption. The identification of shared molecular targets, including LARP1 and TFEB, provides new mechanistic insight and supports the potential development of cannabinoid-based therapeutic strategies for cholangiocarcinoma. Full article

Hyaluronic acid (HA) is widely used in skincare, but its efficacy varies with molecular weight (MW), affecting its skin penetration and activity. This study examined whether HA20, a broad-MW HA complex (weight-average MW: 188 kDa, 10–1000 kDa), improves skin absorption and shields human skin models from environmental stress. HA transepidermal bioavailability, extracellular-matrix responses, glyoxal-induced Nε-(carboxymethyl)lysine (CML), UVA-induced mitochondrial membrane potential (MMP) loss, Th2 cytokine-induced markers, and dryness-induced barrier changes were assessed in reconstructed human epidermis, dermal fibroblasts, and epidermal keratinocytes. HA20 exhibited greater apparent permeation detectable by ELISA at all time points during the 24 h RHE assay compared to high-MW HA. In fibroblasts, 0.05% HA20 increased type I collagen secretion from 535.20 to 585.47 pg/mL and elastin from 8.68 to 9.24 pg/mL, reduced CML fluorescence to 70.13% of the glyoxal control, and increased MMP-associated fluorescence from 58.76% in the UVA model group to 298.86%. In keratinocytes, 0.1% HA20 reduced IL-4/IL-13-induced NELL2 and CAII expression. Under acute dryness, HA20 maintained stratum corneum morphology and altered transcriptomic signatures related to epidermal differentiation, extracellular matrix organization, and barrier-associated genes, including KRT37, COL7A1, ACER2, and SPRR1A. These findings suggest that HA20 supports barrier resilience mainly through improved transepidermal delivery and ECM or barrier-repair responses. Full article

Background: Recurrent pregnancy loss (RPL) is frequently linked to antiphospholipid antibodies, yet many affected women are seronegative for the classical (Sydney) criteria antibodies. In a previously characterized cohort, an extended antiphospholipid antibody panel was positive in 79% of women with RPL, with the strongest associations for antibodies against prothrombin, annexin V and β₂-glycoprotein I. Whether this association reflects molecular endometrial dysfunction was unclear. Objective: To examine endometrial expression of ten decidualization- and inflammation-related genes in women with RPL, stratified by APL status, focusing on the dominant antibody specificity: anti-β₂-glycoprotein I. Methods: Thirty-nine women with RPL (≥2 losses), a subsample of a published 100-patient cohort, underwent mid-luteal Pipelle endometrial biopsy followed by RT-PCR for C4BPA, CXCL1, HAND2, HPRT1, IFNG, IL15, IL8 (CXCL8), MMP10, TNC and VEGFB. Antibodies were measured by antiphospholipid 10 Dot line immunoblot (Generic Assays, Germany). The analysis used Mann–Whitney U, Fisher’s exact test, Benjamini–Hochberg correction and ROC analysis. Results: Antibody prevalence in the subsample matched the parent cohort (Pearson r = 0.999). Of ten transcripts, only HAND2 showed a nominally significant reduction in APL+ women (median ΔCt −2.04 vs. −1.30; p = 0.037; rank-biserial r = −0.47); this signal did not survive Benjamini–Hochberg correction (q = 0.372). The signal was specific to anti-β₂GPI (p = 0.064; AUC 0.700), not to annexin V or prothrombin. A cut-off of HAND2 ΔCt ≤ −1.60 identified APL+ status with 73% sensitivity, 78% specificity and OR 9.62 (95% CI 1.64–56.4; p = 0.015). HAND2 clustered with IL15 (ρ = 0.65) and VEGFB (ρ = 0.70). Conclusions: Anti-β₂-glycoprotein I antibodies, the dominant APL specificity in RPL, are associated with reduced endometrial HAND2 expression. This exploratory data outline a candidate molecular pathway linking extended antiphospholipid serology to impaired endometrial receptivity. Full article

Heart failure with preserved ejection fraction (HFpEF) is an increasingly common form of heart failure (HF) that is best understood as a systemic, multiorgan syndrome rather than a disease of left-ventricular filling alone. This review has three specific aims: first, to synthesize genetic and molecular pathways that are most relevant to non-ischemic HFpEF; second, to distinguish HFpEF-enriched mechanisms from evidence extrapolated from ischemic cardiomyopathy or HFrEF; and third, to consider translational implications for populations with high consanguinity, including the Kingdom of Saudi Arabia. The available evidence indicates that chronic inflammatory signaling involving CCL2, CCL5, TLR3, PTGS2/COX-2, IL-6/JAK/STAT3, NF-kB, and NLRP3 acts upstream of endothelial dysfunction, nitric-oxide/cGMP/PKG impairment, mitochondrial reactive oxygen species generation, and fibroblast activation. Extracellular-matrix regulators including ASPN, COL1A1, and MMP2 then amplify collagen deposition and myocardial stiffness, whereas mitochondrial genes and proteins such as ATP5C1 contribute to impaired oxidative phosphorylation, reduced ATP reserve, defective fatty-acid oxidation, and blunted mitophagy. Protein-quality-control pathways involving HSP90AA1, CCT2/CCT5, PSMA3, and stress-responsive STAT3 further link metabolic stress to proteotoxic injury. Epigenetic mechanisms, including DNA methylation and microRNAs such as miR-155, miR-1297, and miR-4649-3p, add a regulatory layer that may improve risk stratification but remains insufficiently validated for routine clinical use. In high-consanguinity settings, recessive cardiomyopathy variants can cluster in families and contribute to earlier NIHF presentations; however, population-level HFpEF-specific variant frequencies remain limited, and findings from HFrEF or dilated cardiomyopathy should be interpreted as candidate pathway evidence rather than definitive HFpEF markers. Translationally, SGLT2 inhibitors, mineralocorticoid-receptor antagonism, biomarker panels, and structured genetic evaluation provide the most clinically actionable bridge from molecular mechanisms to precision HFpEF care. Full article

Idiopathic pulmonary fibrosis (IPF) is one of the most severe forms of idiopathic interstitial pneumonia. Increasing evidence indicates that the gradual accumulation of senescent fibroblasts and alveolar epithelial cells contributes significantly to IPF pathogenesis, suggesting senescence as a potentially targetable process. Recurrent injury to the alveolar epithelium promotes senescence in epithelial cells, impairing their regenerative capacity and thereby predisposing the tissue to fibrotic degeneration. Although epithelial senescence is strongly implicated in the initiation and progression of lung fibrosis, the mechanisms through which it drives IPF remain challenging, partially due to the lack of physiologically relevant in vitro models capable of recapitulating lung architecture under both normal and pathological conditions. The objective of the present study was to develop a reproducible alveolosphere model in healthy and senescent conditions as a preliminary approach to investigate epithelial features that may be relevant to aspects of the IPF microenvironment. An alveolosphere system was generated by culturing alveolar epithelial cells with or without basement membrane components in combination with alveolar/epithelial optimized medium. Cultures were maintained for 3, 6, and 8 days, and cell viability together with morphological assessment confirmed the absence of cytotoxicity. The expression of keratin 8/18 and AQP5 was consistent with the maintenance of epithelial and alveolar-associated features. Cellular senescence was induced by exposing alveolospheres to doxorubicin for 24 h. Subsequent analyses of viability, along with the expression of senescent and pro-fibrotic markers, inflammatory mediators, and tissue remodeling factors, such as MMPs, were carried out in senescent 3D structures. The results demonstrated robust cell viability at all time points, supported by morphological observations. Marker expression suggested preservation of key epithelial characteristics, while senescence-inducing conditions were associated with an increase in senescence-associated, pro-fibrotic, inflammatory, and matrix-modulating markers. Collectively, these findings describe the preliminary establishment of a cost-effective and reproducible alveolosphere platform that may represent a useful starting point for studying epithelial senescence and its potential association with pro-fibrotic signaling relevant to aspects of IPF pathogenesis. Furthermore, this model may provide a basis for the preliminary evaluation of senotherapeutic compounds aimed at delaying or preventing the onset of cellular senescence. Full article

Postoperative wound healing complications present a major challenge in plastic and reconstructive surgery, prolonging recovery and impairing outcomes. Early risk identification is difficult due to complex interactions among clinical, laboratory, and molecular factors. This study developed and evaluated machine-learning (ML) models to predict wound healing outcomes and identify key complication predictors. Utilizing a dataset of 95 women and 76 variables (including hematological, biochemical, coagulation, and gene expression profiles), we evaluated several ML approaches, including Decision Tree, Extra Trees, Gaussian/Bernoulli Naive Bayes, Logistic Regression, and Support Vector Machine. Model performance was assessed via k-fold cross-validation, ROC analysis, and SHAP feature importance. Molecular markers (COL1A1, MMP9, MAPK1, MAPK8, IL10, and CCL2) emerged as the strongest predictors, whereas conventional clinical variables showed limited value. The models achieved high discriminative performance, with validation ROC–AUC values ranging from 0.903 to 0.913. Extra Trees and Gaussian Naive Bayes demonstrated the highest sensitivity for detecting complications (Recall = 0.820 ± 0.238 and 0.807 ± 0.246, respectively). These findings highlight the value of integrating molecular-genetic biomarkers with ML for personalized risk stratification and preventive care in reconstructive surgery. Full article

Despite reducing hernia recurrence, synthetic meshes often trigger persistent foreign body responses (FBRs). Mesh-enriched therapies (METs), incorporating autologous cellular components (MSCs, PRP, SVF), can regeneratively reprogram the host-prosthetic interactome. Following PRISMA-ScR guidelines, this scoping review involved a systematic search of PubMed, Embase, and Scopus (2000–2025). We utilized the PCC (Population, Concept, Context) framework to map evidence across systemic inflammation, local FBR, and bio-augmentation strategies. A total of sixty-five studies were synthesized and categorized into three primary thematic pillars. Regarding the Systemic Response (n = 25), the data established a predictable “foreign body signature” characterized by prominent C-reactive protein (CRP) and interleukin-6 (IL-6) spikes within the first 48 h post-implantation. For the Local Foreign Body Reaction (FBR, n = 19), human explant data extending up to 180 months revealed a perpetual, immune-mediated state driven by matrix metalloproteinase-2 (MMP-2) matrix remodeling and the development of “bridging fibrosis.” Finally, concerning Mesh-Enriched Therapy (MET) Integration (n = 21), biological enrichment successfully shifted the M1/M2 macrophage ratio toward a pro-regenerative, CD163+/CD206+ phenotype. While MET consistently enhanced vascular endothelial growth factor (VEGF)-driven angiogenesis and optimized the Collagen I/III ratio, a notable 22.2% discrepancy rate across the literature underscores the critical need for precise transforming growth factor-beta 1 (TGF-β1) dosing and release kinetics to prevent hyper-fibrosis. MET shifts hernia repair from passive mechanical reinforcement to active “biocamouflage” and integration. By modulating the Th1/Th2 rheostat, enriched therapies mitigate chronic inflammation and long-term complications. Standardized clinical trials are essential to optimize the therapeutic window for hybrid integration. Full article

Cancer remains one of the most frightening global health challenges, contributing substantially to morbidity and mortality across diverse populations. In recent years, naturally derived compounds have attracted considerable attention due to their potential therapeutic efficacy and fewer adverse effects. Among these, the flavokawain subclass of chalcones, comprising Flavokawains A, B, and C, obtained from various plant sources, has emerged as a promising group of bioactive phytochemicals exhibiting a broad spectrum of pharmacological activities, with notable anticancer potential. This review critically compiles and evaluates the existing preclinical evidence regarding the anticancer mechanisms of flavokawains across various cancer models. It was found that these compounds have significant potential to inhibit cancer cell proliferation, induce apoptosis, disrupt cell-cycle progression, and modulate multiple molecular pathways implicated in tumorigenesis, including phosphoinositide 3 kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), extracellular-signal regulated kinase/c-Jun N-terminal kinase/mitogen-activated protein kinase (ERK/JNK/MAPK) and so on. Importantly, flavokawains exert significant modulatory effects within the tumor microenvironment by suppressing angiogenesis through downregulation of vascular endothelial growth factor (VEGF) and Angiopoietin-1 (Ang-1), attenuating epithelial-mesenchymal transition via restoration of E-cadherin and suppression of vimentin and Snail1, inhibiting matrix metalloproteinase (MMP)-mediated extracellular matrix remodeling, and disrupting cancer stem cell (CSC)-supportive niches. Preclinical toxicity profiles suggest a favorable safety margin, though further investigation is required to fully elucidate their therapeutic index. Due to their multifaceted mechanisms of action and selective cytotoxicity toward cancer cells, flavokawains are considered promising preclinical candidates for development as adjuncts or alternatives to conventional chemotherapeutic agents. Full article

Background: Tooth enamel is the hardest and most highly mineralized tissue in the human body. It serves as a protective barrier against chemical, mechanical, and microbial challenges. Despite its durability, enamel remains vulnerable to developmental and posteruptive defects such as fluorosis, hypomineralization, and amelogenesis imperfecta (AI). For oral health professionals, a clear understanding of the biological and molecular mechanisms underlying enamel formation is essential for advancing preventive and therapeutic strategies in clinical practice. This review synthesizes current knowledge on enamel formation, with emphasis on its cellular, molecular, and structural determinants, and discusses clinically relevant disruptions as well as emerging biomimetic approaches. Methods: This scoping review was conducted according to the PRISMA-ScR guidelines. A systematic literature search of the mechanisms of enamel formation was performed via Embase and Medline. Titles and abstracts were screened independently by three authors. Studies that primarily addressed enamel defects were excluded from the systematic synthesis; however, these studies were retained for narrative discussion. Following the screening process, 92 publications met the inclusion criteria and were incorporated into the thematic synthesis. Results: Enamel formation is a complex, multistage process involving epithelial–mesenchymal interactions and the sequential activity of ameloblasts during presecretory, secretory, transition, and maturation stages. Key mechanisms include the secretion of enamel matrix proteins (e.g., amelogenin, ameloblastin, and enamelin), proteolytic processing by enzymes such as MMP20 and KLK4, and controlled ion transport, leading to hydroxyapatite crystal growth and organization into rod and interrod structures. The structural arrangement endows enamel with exceptional mechanical resistance. Narrative sections address “What can go wrong?”, summarizing genetic, epigenetic, and environmental causes of fluorosis, hypomineralization, and amelogenesis imperfecta, and other developmental defects, whereas “What can we learn from nature?” highlights biomimetic strategies. Conclusions: Human enamel formation is a highly coordinated biomineralization process regulated at the cellular, structural, and molecular levels. Disruptions in these processes underlie major enamel pathologies. Integrating mechanistic insights from natural enamel development with emerging biomimetic technologies offers promising avenues for prevention, diagnosis, and treatment in dentistry. This review provides oral health professionals with a biologically grounded framework to guide evidence-based management of enamel-related conditions. Full article

Background: Available data indicate that the development of refractory schizophrenia may result from neuroinflammation, dysregulation of neurotrophins and metalloproteinases (MMPs), oxidative stress (OS), and hormonal imbalance. Electroconvulsive therapy (ECT) is an effective therapeutic option for drug resistance, but its impact on brain-derived neurotrophic factor (BDNF) and MMPs remains underinvestigated. This study evaluates the influence of ECT on serum BDNF, MMPs (MMP-7, MMP-9, MMP-14), and tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2, TIMP-3) in patients with treatment-resistant schizophrenia (TRS). Another goal of this study is an assessment of the relationships between these biomarkers and the intensity of schizophrenia symptoms. Methods: Serum concentrations of the aforementioned biomarkers were measured prior to and after ECT in eight patients and 13 healthy controls. The severity of schizophrenia symptoms was evaluated with the Positive and Negative Syndrome Scale (PANSS). Results: Bayesian analysis comparing pre-ECT serum concentrations of BDNF, MMPs, and their inhibitors in TRS patients with a control group showed a significant difference only for MMP-9. Furthermore, convincing evidence of a correlation between MMP-9 and MMP-14 was found in TRS patients. Although the ECT therapy did not result in changes in the serum concentrations of the studied biomarkers, substantial improvement in schizophrenia symptoms on the PANSS was observed. Conclusions: No significant biomarker changes (post- versus pre-treatment) were detected in this small exploratory cohort. Whether these biomarkers are involved in neuroinflammation (as possible contributors to the development of TRS) remains an open question, and therefore, further research on biomarkers in cerebrospinal fluid (CSF) may be suggested. Full article

Bovine Mycoplasma bovis pneumonia (MBP) is an important component of bovine respiratory disease, and its management is complicated by persistent infection and antimicrobial stewardship concerns. Houttuynia cordata Thunb. has reported anti-inflammatory and immunomodulatory activities, but its potential host-directed mechanisms in MBP remain unclear. This in silico study used network pharmacology and molecular docking to identify candidate compounds, common drug–disease targets, enriched biological functions, and predicted ligand–target interactions. A total of 145 putative targets of H. cordata and 474 MBP-associated disease targets were obtained from TCMSP, GeneCards, OMIM, and CTD, yielding 43 common drug–disease targets. Dual-confidence STRING analysis, cytoHubba ranking, and MCODE module analysis prioritized TNF, IL6, IL1B, PTGS2, PPARG, IFNG, CASP3, and MMP9 as candidate core targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment indicated convergence on cytokine-mediated signaling, inflammatory response, immune regulation, oxidative stress, IL-17 signaling, and TNF signaling. Molecular docking suggested favorable predicted interactions for quercitrin–PTGS2, quercetin–TNF, quercetin–IL6, and quercitrin–CASP3. These computational findings suggest that H. cordata may be associated with host inflammatory and immune-response modulation in MBP, mainly through flavonoid-related interactions with inflammation- and apoptosis-related targets. Further bovine-specific experimental validation is required before biological activity or practical application can be inferred. Full article

Myocardial infarction (MI) is a leading cause of mortality worldwide. Identification of robust and translatable molecular markers remains challenging due to inter-dataset and inter-species variability. In this study, we performed a cross-species integrative analysis to identify conserved hub genes and potential therapeutic targets in MI. Analysis revealed five hub genes (IL6, SERPINE1, MMP14, PLAUR, and ENO1), which were consistently validated across human peripheral blood and multiple animal models. A multigene diagnostic model demonstrated strong predictive performance (AUC = 0.904). The model was developed to distinguish myocardial infarction (MI) samples from non-MI control samples in an independent peripheral blood dataset. Drug–gene interaction analysis identified candidate therapeutic compounds. These results are computational predictions from the DGIdb database and do not represent validated therapeutic effects in myocardial infarction. These findings highlight conserved molecular mechanisms of MI and provide potential biomarkers and therapeutic targets with translational relevance. Full article

Equine osteoarthritis (OA) is a major cause of lameness and economic loss in horses. While platelet-rich plasma (PRP) has clinical potential, the biological effects of fresh PRP (F-PRP) and freeze-dried PRP (FD-PRP) remain insufficiently defined. This pilot study compared 25% and 50% F-PRP and FD-PRP in an interleukin-1β-induced equine cartilage-synovium explant co-culture model. PRP treatments reduced inflammatory responses, with significant downregulation of COX-2 and PGE2 expression, and 25% F-PRP showed the most consistent inhibition of nitric oxide production. PRP also significantly reduced glycosaminoglycan release and altered matrix-related gene expression; however, FD-PRP significantly upregulated MMP13, indicating a potential pro-catabolic response. Untargeted LC/MS metabolomics showed that F-PRP and FD-PRP were associated with changes in glucose, purine, amino acid, lipid, and nucleotide metabolism. Growth factor analysis further showed lower PDGF and TGF-β1 concentrations in FD-PRP than in F-PRP. Overall, F-PRP showed more consistent anti-inflammatory and matrix-protective effects, whereas FD-PRP requires further optimization and safety validation before clinical application. Full article

The protective effect of Compound terminalia chebula extract (HL) against colonic injury induced by Porcine epidemic diarrhea virus (PEDV) infection in neonatal piglets remains unclear. This study aimed to evaluate the mitigating effects of HL on PEDV-induced colonic injury and elucidate the underlying mechanisms. Eighteen 7-day-old Duroc × Landrace × Large White piglets (2.58 ± 0.05 kg) were randomly assigned to three groups (n = 6/group): CON (blank control), PEDV (infected), and HL + PEDV (HL-supplemented + infected). The 11-day trial included 3 days of acclimatization (days 0–3) and an 8-day experimental period (days 4–11). HL (10 mg/kg BW) was orally administered daily to the HL + PEDV group. On day 8, PEDV and HL + PEDV groups were challenged with 3 mL PEDV (3 × 10⁶ TCID₅₀/mL), while CON received Dulbecco’s Modified Eagle Medium (DMEM). All piglets were euthanized on day 11 for colonic tissue collection. Results indicated that PEDV infection induced colonic injury, manifested by a significant increase in crypt depth and disruption of intestinal homeostasis. This was evidenced by impaired barrier integrity (upregulation of matrix metalloproteinase-7 gene [MMP7] and matrix metalloproteinase 13 gene [MMP13], mucus disorganization (elevation of mucin 5AC gene [MUC5AC]), oxidative stress (reduced catalase [CAT] activity and increased malondialdehyde [MDA] levels in serum and colon), and inflammation (upregulation of regenerative islet-derived protein 3γ gene [REG3G], S100 calcium-binding protein A8/A9 gene [S100A8/A9], and interleukin-1β gene [IL-1β]). Additionally, PEDV impaired colonic ion transport by downregulating calcium channel genes (Transient Receptor Potential Cation Channel Subfamily V Member 6 gene [TRPV6], Transient Receptor Potential Cation Channel Subfamily M Member 6 gene [TRPM6]). Notably, HL supplementation effectively reversed these adverse effects. HL restored colonic morphology, increased CAT activity, reduced MDA accumulation, and suppressed inflammatory gene expression. Furthermore, HL modulated the expression of genes involved in water and ion transport upregulating Aquaporin 7 gene (AQP7), Chloride Channel Accessory 4 gene (CLCA4), Sodium-Hydrogen Exchanger 3 gene (NHE3), Transient Receptor Potential Vanilloid 6 (TRPV6), and Transient Receptor Potential Melastatin 6 gene (TRPM6) and significantly inhibited PEDV replication, as indicated by the downregulation of the transcription levels of PEDV membranegene (M), nucleocapsid gene (N), and spike gene (S). Taken together, HL alleviates PEDV-triggered colonic tissue damage in suckling piglets via improving colonic antioxidant capacity, mitigating inflammatory response, partially regulating intestinal barrier and ion/water transport-related genes, and downregulating the transcription of PEDV structural genes at molecular and histological levels. Full article